

Global and China Stem Cell Industry Report, 2015-2018

<https://marketpublishers.com/r/G11280FE15FEN.html>

Date: November 2015

Pages: 120

Price: US\$ 2,400.00 (Single User License)

ID: G11280FE15FEN

Abstracts

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research.

Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out.

Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia.

Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies.

In February 2015, Ministry of Science and Technology of the People's Republic of

China published the Stem Cell and Translational Medicine Implementation Plan of National Key R&D Program (Draft). In August 2015, CFDA (China Food and Drug Administration) issued Management on Clinical Stem Cell Experimental Study (Trial). With the relaxation of policies, the stem cell industry has attracted Chinese investors once again.

On December 4, 2014, Xi'an International Medical Investment (formerly known as Kaiyuan Investment) announced to invest RMB270 million in acquiring 34% stake in H & B's registered capital in order to accelerate the development of health care services and foster new profit engines.

On April 17, 2015, Yinhe Investment proclaimed that it would associate with its controlling shareholder Yinhe Group to jointly lavish RMB2 billion in the establishment of Biomedical M&A Fund whose total size hits RMB6 billion. The fund is mainly used for immunotherapy, stem cell clinical application platforms, macromolecular drugs, antibody drug development and other fields.

On October 27, 2015, Ningxia Xinri Hengli Steel Wire Rope Co., Ltd. released a restructuring plan to take over 80% stake in BoyaLife from Xu Xiaochun, Maoxing Investment Management (Hangzhou), Yang Lijuan, Wang Jianrong, etc. with RMB1.5656 billion.

Global and China Stem Cell Industry Report, 2015-2018 highlights the followings:

Classification, application, industry chain definition, etc. of stem cells;

Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;

Policies, upstream/midstream/downstream development, etc. of China stem cell industry;

Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide.

Contents

1. OVERVIEW OF STEM CELL INDUSTRY

- 1.1 Definition
- 1.2 Classification and Application
- 1.3 Industry Chain
- 1.4 Development Course

2. GLOBAL STEM CELL INDUSTRY CHAIN

- 2.1 Industry Chain Layout of Major Enterprises
- 2.2 Policy
- 2.3 Development
- 2.4 Upstream
- 2.5 Downstream
- 2.6 Prospect

3. CHINA STEM CELL INDUSTRY CHAIN

- 3.1 Development
- 3.2 Policy
- 3.3 Upstream
- 3.4 Midstream
- 3.5 Downstream

4. UPSTREAM ENTERPRISES

- 4.1 Cryo-Cell International
 - 4.1.1 Profile
 - 4.1.2 Operation
 - 4.1.3 Cord Blood Business
- 4.2 Esperite
 - 4.2.1 Profile
 - 4.2.2 Operation
 - 4.2.3 Revenue Structure
 - 4.2.4 Stem Cell Business
- 4.3 VCANBIO
 - 4.3.1 Profile

- 4.3.2 Operation
- 4.3.3 Revenue Structure
- 4.3.4 Gross Margin
- 4.3.5 R&D and Investment
- 4.3.6 Stem Cell Business
- 4.3.7 Development Forecast
- 4.4 Golden Meditech
 - 4.4.1 Profile
 - 4.4.2 Operation
 - 4.4.3 Revenue Structure
 - 4.4.4 Cord Blood Business
 - 4.4.5 Development Forecast
- 4.5 LifeCell International
 - 4.5.1 Profile
 - 4.5.2 Cord Blood Business
- 4.6 Cryosite
 - 4.6.1 Profile
 - 4.6.2 Operation
 - 4.6.3 Revenue Structure
 - 4.6.4 Stem Cell Business
- 4.7 Health & Biotech
 - 4.7.1 Profile
 - 4.7.2 Operation
- 4.8 Tian Qing Stem Cell
 - 4.8.1 Profile
 - 4.8.2 Operation
 - 4.8.3 Revenue Structure

5. MIDSTREAM AND DOWNSTREAM ENTERPRISES

- 5.1 Caladrius Biosciences
 - 5.1.1 Profile
 - 5.1.2 Operation
 - 5.1.3 Revenue Structure
 - 5.1.4 R&D and Investment
 - 5.1.5 Stem Cell Business
- 5.2 Mesoblast
 - 5.2.1 Profile
 - 5.2.2 Operation

- 5.2.3 R&D and Investment
- 5.2.4 Stem Cell Business
- 5.3 MEDIPOST
 - 5.3.1 Profile
 - 5.3.2 Operation
 - 5.3.3 Stem Cell Business
- 5.4 Beike Biotechnology
 - 5.4.1 Profile
 - 5.4.2 Stem Cell Business
- 5.5 Osiris Therapeutics
 - 5.5.1 Profile
 - 5.5.2 Operation
 - 5.5.3 R&D
- 5.6 Orthofix International
 - 5.6.1 Profile
 - 5.6.2 Operation
 - 5.6.3 Revenue Structure
 - 5.6.4 R&D
 - 5.6.5 Stem Cell Business
- 5.7 Cytori Therapeutics
 - 5.7.1 Profile
 - 5.7.2 Operation
 - 5.7.3 R&D
- 5.8 Athersys
 - 5.8.1 Profile
 - 5.8.2 Operation
 - 5.8.3 R&D
- 5.9 Pluristem Therapeutics
 - 5.9.1 Profile
 - 5.9.2 R&D and Recent News
- 5.10 StemCells
 - 5.10.1 Profile
 - 5.10.2 Operation
 - 5.10.3 R&D
- 5.11 Ocata
 - 5.11.1 Profile
 - 5.11.2 Operation
 - 5.11.3 R&D
- 5.12 Celgene

- 5.12.1 Profile
- 5.12.2 Operation
- 5.12.3 R&D
- 5.13 Vitro Biopharma
 - 5.13.1 Profile
 - 5.13.2 Operation
 - 5.13.3 R&D
 - 5.13.4 Stem Cell Business
- 5.14 Reneuron
 - 5.14.1 Profile
 - 5.14.2 Operation
 - 5.14.3 R&D
- 5.15 Tigenix
 - 5.15.1 Profile
 - 5.15.2 Operation
 - 5.15.3 R&D
- 5.16 Cellular Biomedicine
 - 5.16.1 Profile
 - 5.16.2 Operation
 - 5.16.3 R&D
 - 5.16.4 Stem Cell Business
 - 5.16.5 Business in China
- 5.17 SALIAI
 - 5.17.1 Profile
 - 5.17.2 Operation
 - 5.17.3 Stem Cell Business
- 5.18 Opexa Therapeutics
- 5.19 ZhongKe Biopharm
- 5.20 Cyagen Biosciences

Selected Charts

SELECTED CHARTS

Classification of Stem Cell

Overview of Stem Cell Therapy Area (by Disease Type)

Advantages and Disadvantages of Stem Cell Therapy

Source and Application of Adult Stem Cells (by Type)

Stem Cell Industry Chain

Industry Chain Distribution of Major Global Stem Cell Enterprises

Policy Tendency of Human Embryonic Stem Cell Research Worldwide

Stem Cell Products Granted 'Orphan Drug' by EU EMEA

Global Authorized Stem Cell Varieties

Top 20 Indications of Global In-research Stem Cell by the end of 2014

Global Stem Cell Products in Late R&D Stage

Global Stem Cell Market Size and YoY Growth, 2007-2014

Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2014

Distribution of Cord Blood-related Research Projects Registered in the US National Institutes of Health, by Nov 17, 2015

Clinical Application of Global Stem Cell Technology (by Disease Type), 2014

Cord Blood Bank Distribution in Major Countries by the end of 2014

Cord Blood Application in Major Countries

Global Top 10 Death Causes (by Death Toll), 2012

Global Top 10 Death Causes (by Income Group), 2012

Global Top 10 Death Causes in Low-income Countries, 2012

Global Top 10 Death Causes in Low- and Middle-income Countries, 2012

Global Top 10 Death Causes in Middle- and High-income Countries, 2012

Global Top 10 Death Causes in High-income Countries, 2012

Application Prospect of Global Stem Cell

Global Stem Cell Market Size and YoY Growth, 2014-2018E

Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA

Construction of Chinese Stem Cell Industrialization Bases

China's Stem Cell Industry Policies, 1999-2015

Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry

Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry

Chinese Stem Cell Medical Market Size and YoY Growth, 2007-2018E

Revenue and Net Income of Cryo-Cell International, FY2010-FY2015

Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014

Cord Blood Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2015

Revenue and Net Income of Esperite, 2010-2015

Revenue of Esperite (by Business), 2010-2015

Revenue Structure of Esperite (by Region), 2014

Stem Cell Storage of Esperite, 2009-2014

Stem Cell Storage Revenue and EBITA of Esperite, 2010-2015

Operation of Main Subsidiaries of VCANBIO by 2015H1

Revenue and Net Income of VCANBIO, 2010-2015

Revenue of VCANBIO (by Business), 2011-2015

Revenue of VCANBIO (by Region), 2011-2015

Gross Margin of VCANBIO (by Business), 2011-2015

R&D Costs and % of Total Revenue of VCANBIO, 2011-2015

Fund-raising Investment Projects and Progress of VCANBIO, by Jun 30, 2015

Stem Cell Storage Business of VCANBIO (by Type), 2009-2014

Revenue and Net Income of VCANBIO, 2014-2017E

Revenue and Net Income of Golden Meditech, FY2009-FY2014

Revenue of Golden Meditech (by Business), FY2009-FY2014

Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014

Cord Blood Bank Gross Profit and Gross Margin of Golden Meditech, FY2011-FY2014

Development Course of Golden Meditech's Cord Blood Storage Business

Revenue and Net Income of Golden Meditech, FY2014-FY2018E

Development Course of LifeCell International

Revenue and Net Income of Cryosite, FY2011-FY2015

Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014

Equity Structure of Health & Biotech

Industry Base Distribution of Health & Biotech

Revenue and Net Income of Health & Biotech, 2012-2014

Revenue and Net Income of Tian Qing Stem Cell, 2013-2015

Revenue (by Business) of Tian Qing Stem Cell, 2013-2015

Subsidiaries of Caladrius Biosciences, by the end of 2014

Revenue and Net Income of Caladrius Biosciences, 2009-2015

Revenue (by Business) of Caladrius Biosciences, 2012-2015

R&D Costs and % of Total Revenue of Caladrius Biosciences, 2009-2014

M & A Course of Caladrius Biosciences, 2009-2014

Revenue and Net Income of Mesoblast, FY2009-FY2015

R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2015

M&A Course of Mesoblast by the end of 2014

Stem Cell Product R&D Progress of Mesoblast by the end of June 2015
Revenue and Net Income of MEDIPOST, 2011-2014
Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
Development Course of Beike Biotechnology
Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
Revenue, Net Income and Gross Margin of Osiris Therapeutics, 2011-2015
R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2015
Revenue, Net Income and Gross Margin of Orthofix International, 2009-2014
Revenue of Orthofix International (by Department), 2011-2015
R&D Costs and % of Total Revenue of Orthofix International, 2011-2015
Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2010-2015
Revenue of Cytori Therapeutics (by Region), 2010-2015
R&D Costs and % of Total Revenue of Cytori Therapeutics, 2010-2015
Revenue and Net Income of Athersys, 2010-2015
Revenue of Athersys (by Source), 2010-2015
R&D Costs and % of Total Revenue of Athersys, 2010-2015
Significant Cooperative Partners and Areas of Athersys
Revenue and Net Income of StemCells, 2011-2015
R&D Costs and % of Total Revenue of StemCells, 2011-2015
Stem Cell Product R&D, Therapeutic Area and Progress of StemCells by 2015H1
Revenue, Net Income and Gross Margin of Ocata, 2010-2015
R&D Costs and % of Total Revenue of Ocata, 2010-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Ocata by the end of 2014
Revenue, Net Income and Operating Margin of Celgene, 2009-2014
Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
Revenue and Net Income of Vitro Biopharma, FY2009-FY2015
R&D Costs and % of Total Revenue of Vitro Biopharmas, FY2009-FY2015
Stem Cell Brands and Application Fields of Vitro Biopharma
Revenue and Net Income of Reneuron, FY2010-FY2015
R&D Costs and % of Total Revenue of Reneuron, FY2010-FY2015
Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2014
Revenue and Net Income of Tigenix, 2009-2015
Sales of Tigenix (by Region), 2011-2013
R&D Costs and % of Total Revenue of Tigenix, 2012-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Tigenix by 2015H1
Development Course of Cellular Biomedicine
Revenue and Net Income of Cellular Biomedicine, 2013-2015

R&D Costs and % of Total Revenue of Cellular Biomedicine, 2013-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Cellular Biomedicine by
2015H1
Revenue and Net Income of SALIAI, 2013-2015

I would like to order

Product name: Global and China Stem Cell Industry Report, 2015-2018

Product link: <https://marketpublishers.com/r/G11280FE15FEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G11280FE15FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970